Vincent Ma
@VincentMaMD
Followers
148
Following
138
Statuses
44
Melanoma/Cutaneous Medical Oncologist @UWCarbone
Madison, WI
Joined March 2019
RT @JournalCancer: New and #OpenAccess from @VincentMaMD et al: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with sta…
0
1
0
Landmark results from the #NADINA trial, presented at #ASCO24! A study that is paving the way for response adapted treatment of melanoma. #Neoadjuvant #Immunotherapy #ASCO24 @ASCO @OncoAlert
Presented at #ASCO24: Among patients who received two 3-week cycles of neoadjuvant ipilimumab and nivolumab, the 12-month event-free survival was 83.7%, as compared with 57.2% among those who received only adjuvant therapy. Full NADINA trial results:
0
2
11
Great job @danny_trotier for this review article on managing periorbital skin malignancies! @uw_hemeoncpc @frontoncology
New research: Review of recent advances in managing periocular skin malignancies: Management of cutaneous malignancies can be particularly challenging when they are located in the periocular region. The standard of care for localized disease is… #oncology
0
0
5
Major milestone today! @US_FDA approves lifileucel, an autologous tumor infiltrating lymphocyte therapy, for previously treated advanced melanoma. This is the first in its class of cellular therapies for solid tumors.
FDA granted accelerated approval to lifileucel for adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor. #OCENewsBurst
0
1
7
@Samantha_July01 @OncLive @UWCarbone Our pilot study (NCT06199713) is accruing unresectable stage III/IV melanoma patients with baseline PET/CT who plan to be treated with ICI
0
0
1
Thank you @OncLive! We are excited to have our pilot study (NCT06199713) active and openly accruing patients with advanced melanoma at @UWCarbone
18F-FDG PET/CT May Serve as Early Interval Response Assessment Tool in Patients Receiving Combinatorial ICI Therapy. @VincentMaMD @UWCarbone #oncology
0
0
3
RT @OncoAlert: The OncoAlert 🚨 Newsletter Now OUT Covering Dec 30-January 4, 2024 REGISTER at: or https://t.co/…
0
18
0
4-year survival updates! Although not a comparative trial between treatment arms, SECOMBIT appears to reaffirm the preferential use of doublet IO as first line followed by BRAFi/MEKi at progression in patients with metastatic BRAF-mutated melanoma. @NatureComms
congrats @PAscierto a landmark paper illuminating the way for BRAF therapy in #melanoma #immunotherapy @NatureComms A must read !!!
0
0
2
Thank you @AIMatMelanoma! I am honored to discuss updates in melanoma care to the Wisconsin community with my colleagues, Drs Mark Albertini, Gloria Xu, and @neuman_heather. @UWCarbone @uw_medicine @uw_hemeoncpc
University of Wisconsin Carbone Cancer Center
0
0
11
Another FDA approved first-line PD-1 inhibitor treatment option for patients with advanced Merkel cell carcinoma
FDA granted accelerated approval to retifanlimab-dlwr (Zynyz, Incyte) for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma. #OCENewsBurst
1
0
3
RT @HTawbi_MD: Incredible achievement positive Phase 3 trial with TIL congrats @HaanenJohn & colleagues @NKI. Game changer/new era to impro…
0
22
0
RT @FrontImmunol: New Research: Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab: Backgro…
0
2
0
RT @sitcancer: Thanks to Vincent T. Ma, MD @uwsmph for joining #SITC at #ASCO22 and for his assistance with the recaps of the scientific hi…
0
1
0
@US_FDA approves its newest checkpoint inhibitor, relatlimab (LAG-3 inhibitor), in combo with nivo for advanced stage melanoma. Recent RELATIVITY-047 results of nivo+rela vs nivo: mPFS (10.2 vs 4.6 mo), mOS (NR vs 34.1 mo), G3/4 trAEs (21.1% vs 11.1%)
0
0
1
RT @jasonlukemd: Major bummer that the #melanoma bem-peg (IL2) + nivo is a neg trial. Field opinion was split on this & the minimal phase 2…
0
9
0
FDA finally approves tebentafusp (KIMMTRAK) as the FIRST systemic treatment for unresectable/metastatic uveal melanoma! #tebentafusp #KIMMTRAK #Immunocore
We are proud to be able to announce that our TCR therapy has been formally approved by the @US_FDA Full announcement:
0
1
3
RT @jasonlukemd: So excited @US_FDA approved today anti-PD1 #immunotherapy pembrolizumab in high-risk stage IIB/C #melanoma! Tx to patients…
0
40
0
RT @UWCarbone: Merkel cell carcinoma, basal cell carcinoma and cutaneous squamous cell carcinoma are just some of the #SkinCancers that our…
0
2
0
RT @PAscierto: At #ESMO2021 #JeffWeber from @NYULangoneLI showed interesting results from triplet ipi/nivo/tocilizumab in the treatment of…
0
11
0
RT @OmidHamidMD: TVEC + Pembro misses the mark vs Pembro. What does this mean for #oncolytic therapy and injectable sin #melanoma ? Asking…
0
16
0